NEURACAP
M&A UpdateUpdated · 7 pages · Free to read

Neurology and CNS Therapeutics M&A update, 14–28 September 2026

This bi-weekly update tracks Neurology and CNS Therapeutics stocks, news flow and M&A across September 14–28, 2026, for investors, operators and advisors who need a fast read on what moved, why, and what closed.

For information only. Not an appraisal or a fairness opinion.

The deeper read: Neurology and CNS Therapeutics Sector Outlook — September 2026

Key figures

Sector median move
-10.7%
25 covered names, close-to-close
S&P 500 return
+0.8%
same two-week period
Xenon Pharmaceuticals (XENE)
-36.9%
two-week price move
ACADIA Pharmaceuticals (ACAD)
-25.4%
two-week price move

Read the report

NeuraCap

BI-WEEKLY INDUSTRY EVENTS & M&A UPDATE

HEALTH CARE › PHARMACEUTICALS, BIOTECHNOLOGY AND LIFE SCIENCES › NEUROLOGY AND CNS THERAPEUTICS

Readouts Repriced the Sector While One Buyer Closed Its Epilepsy Deal

This update covers Neurology and CNS Therapeutics for the two-week period September 14–28, 2026: the movers, the news flow behind them, and the period's one completed transaction.

September 14–28, 2026

Prepared by NeuraCap AI · Confidential

Market data through 2026-09-28 · events and transactions from the two-week period 2026-09-14 → 2026-09-28

Neurology and CNS Therapeutics Bi-Weekly Update | September 14–28, 2026 | Confidential | Not investment advice

1

1 / 7

Executive summary

Across the two-week period, 21 of 25 covered names fell with a median move of -10.7%, while the S&P 500 returned +0.8%, pointing to a sector-specific repricing associated with company announcements rather than the broader market. Xenon Pharmaceuticals Inc. (XENE) fell -36.9% and ACADIA Pharmaceuticals Inc. (ACAD) fell -25.4%, each alongside its own disclosure. Jazz Pharmaceuticals plc (JAZZ) completed an epilepsy-focused acquisition on Sep 15, the period's only closed transaction.

Key findings

  • Sector prices moved on company news, not the broader market this period.
  • 21 of 25 covered names fell; median move was -10.7% vs S&P +0.8%.
  • Xenon (XENE) fell -36.9% and ACADIA (ACAD) -25.4%, each after its own disclosure.
  • Jazz Pharmaceuticals closed an epilepsy acquisition, the period's only deal.

What each page shows

The analyst’s walkthrough of the deck, page by page.

  1. 01
    BI-WEEKLY INDUSTRY EVENTS & M&A UPDATE

    HEALTH CARE › PHARMACEUTICALS, BIOTECHNOLOGY AND LIFE SCIENCES › NEUROLOGY AND CNS THERAPEUTICS

    Cover slide introducing the Neurology and CNS Therapeutics bi-weekly update for September 14–28, 2026.

    We open this bi-weekly update on Neurology and CNS Therapeutics for September 14–28, 2026, covering what changed, who moved, what transacted, and what it means. Let's walk through the period's record together.

    Everything on this page

    BI-WEEKLY INDUSTRY EVENTS & M&A UPDATE HEALTH CARE › PHARMACEUTICALS, BIOTECHNOLOGY AND LIFE SCIENCES › NEUROLOGY AND CNS THERAPEUTICS Readouts Repriced the Sector While One Buyer Closed Its Epilepsy Deal This update covers Neurology and CNS Therapeutics for the two-week period September 14–28, 2026: the movers, the news flow behind them, and the period's one completed transaction. September 14–28, 2026 Prepared by NeuraCap AI · Confidential Market data through 2026-09-28 · events and transactions from the two-week period 2026-09-14 → 2026-09-28 Neurology and CNS Therapeutics Bi-Weekly Update | September 14–28, 2026 | Confidential | Not investment advice Sources & methodology 1

  2. 02
    THE BI-WEEKLY BOTTOM LINE

    Company Announcements, Not the Broad Market, Set Prices Across the Sector

    This page summarizes the two-week period's price moves across the 25 covered names against the S&P 500.

    Across the two-week period, 21 of 25 covered names fell, with a sector median move of -10.7% against a S&P 500 return of +0.8%. That gap tells us the repricing sat inside the sector rather than in the broader market. We read this as evidence that the moves tracked company-level announcements more closely than macro conditions. For anyone tracking this space, the source of the move matters as much as its size.

    Everything on this page

    THE BI-WEEKLY BOTTOM LINE Company Announcements, Not the Broad Market, Set Prices Across the Sector The two-week period in one page · 25 covered names, close-to-close · September 14–28, 2026 Source: NeuraCap analytics platform (universe, prices, filings, transaction records); publisher-sourced news where linked; market data through 2026-09-28. Driver attributions use calibrated language and are NeuraCap reads of the recorded evidence. Neurology and CNS Therapeutics Bi-Weekly Update | September 14–28, 2026 | Confidential | Not investment advice Sources & methodology 2 1 21 of 25 Covered Names Fell; The Median Move Was -10.7% The S&P 500 returned +0.8% over the same two-week period, so the decline sat inside the sector rather than in the market around it. 2 The Largest Declines Landed on the Days Companies Published Xenon Pharmaceuticals Inc. (XENE) ended the two-week period at -36.9% and ACADIA Pharmaceuticals Inc. (ACAD) at -25.4%, with each name's worst session falling on or immediately after its own announcement. 3 One Acquisition Closed While Public Prices Were Falling Jazz Pharmaceuticals plc (JAZZ) completed an acquisition on Sep 15 that adds a clinical-stage precision therapy for KCNT1-related epilepsy. It is the only transaction in this period's record. 4 Tier Membership, Not the Sector Label, Still Frames the Valuation Talk NeuraCap's standing view prices the sector on EV / Revenue, with a sector median of 3.5x, a Premium-tier median of 25.6x and a Discount-tier median of 1.5x. The period's moves were company-specific and sit inside that frame rather than replacing it. +12.3% Best mover — MediciNova, Inc. (MNOV) worst: XENE -36.9% · 4 up / 21 down of 25 covered -10.7% Sector median two-week return vs S&P 500 +0.8% 1 Transaction agreed in the two-week period from company announcements; not yet in the precedent record 1 Company filings in the window 8-K events read for driver attribution

  3. 03
    PUBLIC MARKET MOVERS

    Where the Losses Landed — and What Each Company Had Just Said

    This page details which companies moved the most and links each move to what the company had just disclosed.

    The period's largest declines landed on Xenon Pharmaceuticals Inc. (XENE) at -36.9% and ACADIA Pharmaceuticals Inc. (ACAD) at -25.4%, both against a sector median of -10.7% and a S&P 500 return of +0.8%. We set a materiality bar of 16.9% to separate sector noise from names worth a closer look. Each move on this page is linked to a recorded filing or headline from the window, and where no driver is recorded, we say so plainly. That discipline is what lets us tell you which moves carry information and which don't.

    Everything on this page

    PUBLIC MARKET MOVERS Where the Losses Landed — and What Each Company Had Just Said Bi-Weekly moves, close-to-close · September 14–28, 2026 · sector median -10.7% · S&P 500 +0.8% · materiality bar ±16.9% (sector-relative) Source: NeuraCap analytics platform (universe, prices, filings, transaction records); publisher-sourced news where linked; market data through 2026-09-28. Attribution links each move only to filings and headlines recorded in the window; where no driver is recorded, the page says so. Calibrated language throughout — NeuraCap reads, not asserted causation. Neurology and CNS Therapeutics Bi-Weekly Update | September 14–28, 2026 | Confidential | Not investment advice Sources & methodology 3 Bi-Weekly return per company · teal above zero, amber below · sector median -10.7% Xenon Pharmaceuticals Inc. (XENE) -36.9% Shares moved following the September 17 announcement that Xenon submitted its azetukalner NDA to the FDA for focal seizures and gave an update on its psychiatry clinical programme. The largest single-day fall was -30.7% on Sep 18. Filing the lead indication shifts the debate to the label-expansion programmes standing behind it. COMPANY-SPECIFIC Neumora Therapeutics, Inc. Common Stock (NMRA) -30.8% No notable in-window news was identified that clearly explains the move. At -30.8%, the decline was well beyond the sector median of -10.7%. Clinical-stage names carry the widest moves when no company record anchors the price. UNEXPLAINED ACADIA Pharmaceuticals Inc. (ACAD) -25.4% Shares moved following the Sep 24 Phase 3 enabling topline results from the Phase 2 RADIANT study of remlifanserin in Alzheimer's disease psychosis. That session was the worst of the period at -12.8%. Exclusivity news lands quietly; a Discount-tier name is still priced on its next clinical readout. COMPANY-SPECIFIC MediciNova, Inc. (MNOV) +12.3% MediciNova, Inc. announced last patient, last visit in the double-blind portion of the Phase 2b/3 COMBAT-ALS trial on Sep 24, then MN-001 topline data on Sep 28. The largest single day, +36.9% on Sep 17, preceded both releases. In clinical-stage CNS, completing a registrational programme can be paid for before the data is seen. COMPANY-SPECIFIC

  4. 04
    MAJOR NEWS & INDUSTRY CATALYSTS

    Approvals, a Pipeline Purchase and a Board Fight Carried the News Flow

    This page lists the two-week period's highest-impact news events, including approvals, a pipeline purchase and a board contest.

    This period's news flow was carried by regulatory approvals, a pipeline purchase and a board fight, each linked back to its underlying filing or article. We rank these as the highest-impact events of the window because they are the ones most closely associated with the price moves on the prior page. Our 'why it matters' reads are NeuraCap's interpretation, built only from sources in a fixed reliability order — filings, press releases, then established outlets. Understanding these events is the fastest way to separate durable catalysts from short-term noise.

    Everything on this page

    MAJOR NEWS & INDUSTRY CATALYSTS Approvals, a Pipeline Purchase and a Board Fight Carried the News Flow The two-week period's highest-impact events · titles link to the underlying filing or article · September 14–28, 2026 Source: NeuraCap analytics platform (universe, prices, filings, transaction records); publisher-sourced news where linked; market data through 2026-09-28. "Why it matters" lines are NeuraCap reads; each event links to its source. Sources are admitted in a fixed reliability order (SEC filings, press releases, established outlets); video and social platforms are never used. Neurology and CNS Therapeutics Bi-Weekly Update | September 14–28, 2026 | Confidential | Not investment advice Sources & methodology 4 Sep 16 · NEWS · GlobeNewsWire Biogen's subcutaneous LEQEMBI pen approved in Japan for early Alzheimer's, allowing at-home dosing An at-home administration route shortens the path between diagnosis and first fill for an anti-amyloid therapy. Our read: delivery format now sits alongside the label in the commercial case. Administration burden is a commercial variable in Alzheimer's, not only a clinical one. Sep 15 · NEWS · Business Wire COMPASS Pathways launched a U.S. clinician education programme on treatment-resistant depression Building prescriber understanding ahead of commercialisation targets the depth of the psychiatrist call point, which is where uptake in treatment-resistant depression is decided. Clinical-stage neuropsychiatry names are building prescriber reach before they need it. Sep 15 · NEWS · PRNewsWire Jazz Pharmaceuticals completed an acquisition adding a precision therapy for KCNT1-related epilepsy A Core-tier commercial neurology buyer added a clinical-stage, genotype-defined epilepsy asset while public prices in the space were falling. Our read: appetite is being set by fit with an existing franchise. Defined-genotype epilepsy programmes remain buyable by a field force that already calls on neurologists. Sep 18 · NEWS · GlobeNewsWire An activist shareholder set out a 100-day plan and called for new leadership at Anavex Governance pressure at a clinical-stage Alzheimer's developer is a statement about capital allocation and the credibility of the development plan. Board and spending discipline are part of the value discussion in clinical-stage CNS. Sep 17 · NEWS · GlobeNewsWire Axsome presented ten posters across depression and neurology at Psych Congress 2026 A Core-tier commercial name used a psychiatry congress to show portfolio breadth across marketed and pipeline programmes. Our read: this is how label-expansion optionality is made visible to prescribers. Congress data defends prescriber breadth in the stretch between launches. Sep 17 · NEWS · GlobeNewsWire A proxy adviser backed two dissident nominees for the Anavex board Third-party support raises the odds that strategy and spending at a single-asset clinical-stage name are reset from the top. It follows the shareholder plan published the day before. Contested boards can change the financing posture of a company faster than a readout does.

  5. 05
    M&A & STRATEGIC ACTIVITY

    One Buyer Closed an Epilepsy Acquisition While the Sector Repriced

    This page covers the period's one completed acquisition and places it against 32 recorded precedent transactions.

    Jazz Pharmaceuticals plc (JAZZ) completed an acquisition on Sep 15 that adds a clinical-stage precision therapy for KCNT1-related epilepsy, the only transaction recorded in this two-week window. We compare it against a base of 32 recorded precedent deals to frame how it fits the sector's deal history. Deal multiples on this page are LTM at announcement where disclosed, and our read on deal rationale is drawn only from the recorded evidence. For acquirers watching this space, this is the period's clearest signal of what strategic buyers are willing to close on.

    Everything on this page

    M&A & STRATEGIC ACTIVITY One Buyer Closed an Epilepsy Acquisition While the Sector Repriced September 14–28, 2026 · 1 agreed by company announcement · precedent transactions: 32 recorded deals Source: NeuraCap analytics platform (universe, prices, filings, transaction records); publisher-sourced news where linked; market data through 2026-09-28. Deal multiples are LTM at announcement where disclosed; "why the deal happened" is a NeuraCap read of the recorded evidence. No old transactions are re-presented as news. Neurology and CNS Therapeutics Bi-Weekly Update | September 14–28, 2026 | Confidential | Not investment advice Sources & methodology 5 AGREED IN THE PERIOD — FROM COMPANY ANNOUNCEMENTS Sep 15 · Jazz Pharmaceuticals plc (JAZZ) Jazz Pharmaceuticals plc (JAZZ) completed the purchase of a clinical-stage epilepsy developer The 8-K record shows a commercial neurology buyer paying an upfront cash sum for a clinical-stage asset that fits an epilepsy franchise it already sells into. Our read: strategic fit, not development stage, set the appetite here. Terms and multiples enter the precedent record once the filing is processed; the reference set alongside is unchanged. 32 Recorded precedent transactions the reference set buyers and sellers price against

  6. 06
    WHAT IT MEANS

    What a Data-Driven Two-Week Period and One Closed Deal Mean for You

    This page translates the two-week period's price moves and the one closed deal into implications for owners, acquirers and advisors.

    For owners and operators, the lesson is that prices moved with company announcements this period, so the operating numbers behind each name carry more weight. For acquirers, 21 of 25 covered names fell with a median move of -10.7%, meaning the public comparison set has shifted within the window. For advisors, the throughline is company-level evidence: Xenon Pharmaceuticals Inc. (XENE) at -36.9%, ACADIA Pharmaceuticals Inc. (ACAD) at -25.4%, and Rapport Therapeutics, Inc. (RAPP) at -24.0%, each alongside its own disclosure. Together, these reads point to one conclusion: know what each company said, and when, before pricing anything against it.

    Everything on this page

    WHAT IT MEANS What a Data-Driven Two-Week Period and One Closed Deal Mean for You The two-week period translated for the people who act on it · NeuraCap view · observations, not recommendations Source: NeuraCap analytics platform (universe, prices, filings, transaction records); publisher-sourced news where linked; market data through 2026-09-28. This page is analytical interpretation drawn from the two-week period's recorded evidence. It is not investment advice. Neurology and CNS Therapeutics Bi-Weekly Update | September 14–28, 2026 | Confidential | Not investment advice Sources & methodology 6 Sector study 2026-09-28 EV / Revenue (CY2027E) median 3.5x 26 companies in the study 3 valuation tiers Standing thesis: Neurology and CNS Therapeutics is priced in tiers — and tier membership, not the sector label, sets the conversation FOR OWNERS & OPERATORS Between Readouts, the Commercial Numbers Carry the Story Prices across the space moved with company announcements this two-week period, so the operating base matters more, not less. FOR ACQUIRERS The Reference Set Moved, and One Closing Sets the Live Mark 21 of 25 covered names fell and the median move was -10.7%, so the public comparison points have shifted inside the two-week window. FOR ADVISORS Lead with What the Company Said, and When It Said It The period's theme is company-level evidence setting price: Xenon Pharmaceuticals Inc. (XENE) at -36.9%, ACADIA Pharmaceuticals Inc. (ACAD) at -25.4% and Rapport Therapeutics, Inc. (RAPP) at -24.0%, each alongside its own disclosure.

  7. 07
    SOURCES & METHODOLOGY

    Sources, Methodology and Important Notice

    This page explains the sources and methodology behind every figure and claim in the update.

    Every figure in this update links back to the filing, price record or article it was taken from, and we list the publishers and filings drawn on for the period. Our attribution language is calibrated to the evidence: where a driver is recorded, we say so; where it isn't, we say that too. This transparency is what lets you trust the read without needing to re-verify each number yourself. That's the standard we hold this entire update to.

    Everything on this page

    SOURCES & METHODOLOGY Sources, Methodology and Important Notice How this bi-weekly update is built and what each kind of statement rests on · September 14–28, 2026 · market data through 2026-09-28 Every figure in this update links to the record it was taken from; the publishers and filings drawn on for the period are listed above. Neurology and CNS Therapeutics Bi-Weekly Update | September 14–28, 2026 | Confidential | Not investment advice 7 OBSERVED DATA Bi-Weekly stock moves are computed close-to-close over the stated window from the platform’s price series. Deal records, values and multiples come from the platform’s transaction record (SEC 8-K extractions) exactly as recorded; each figure links to its citation. Treasury rates come from the platform’s Treasury series and are shown only when the 10-year moved at least ten basis points over the window (it did not in this window, so no rate figures appear). UNIVERSE QUALITY The update universe is the platform’s approved company set for this sector, subject to a $100M market-cap floor so small, loosely related names cannot dominate the statistics. 1 name below the floor was excluded from movers and statistics for this window. EVENTS & NEWS Company events are in-window 8-K filings; news items are publisher-sourced headlines fetched for the window (and any externally supplied items, marked as such). Operational and strategic developments (deals, partnerships, launches, expansion, guidance, leadership, regulatory outcomes) are shown first; capital-return mechanics and conference appearances are limited to one each. Every event links to its source. The deck never asserts an event that has no linked record. SOURCE HIERARCHY News is admitted in a fixed order of reliability: SEC filings first, then company press releases and investor-relations communications, then transaction documents, then established outlets (Reuters, CNBC, The Wall Street Journal, Barron’s and peers). Video and social platforms — including YouTube — are never used as sources. DRIVER ATTRIBUTION A stock move is linked to an event only when the event falls inside the window, and only in calibrated language ("the move appears to reflect…", "shares moved following…"). Where no driver is recorded, the page says so and compares the move to the sector median instead. ANALYTICAL INTERPRETATION "Why it matters", "why the deal happened" and the what-it-means page are NeuraCap analytical views drawn from the recorded evidence, and are labeled as such. INHERITED CONTEXT The standing sector view (thesis, valuation lens, sector median and tiering) is inherited from the NeuraCap sector study run_20260929T181134Z_556_prod (market data as of 2026-09-28) — distilled, never re-derived. That report’s own sources page governs its content; this update reads the period against it. IMPORTANT NOTICE This report is informational only. It is not investment advice, not a recommendation to buy or sell any security, and not an offer of any kind. Readers should perform their own diligence before acting on anything described here. Linked sources this two-week period: globenewswire.com · businesswire.com · prnewswire.com

Sources and methodology

This update covers Neurology and CNS Therapeutics over the 14-day window September 14–28, 2026; market data runs through September 28, 2026. The universe is the 25 listed companies whose core business is Neurology and CNS Therapeutics under NeuraCap's industry classification, subject to a $100M market-capitalisation floor so that very small, loosely related names cannot dominate the movers and statistics. Companies covered: ACADIA Pharmaceuticals Inc. (ACAD), Alpha Cognition Inc (ACOG), Amylyx Pharmaceuticals, Inc. (AMLX), Alto Neuroscience, Inc. (ANRO), Anavex Life Sciences Corp. (AVXL), Axsome Therapeutics, Inc. (AXSM), Biohaven Ltd. (BHVN), Biogen Inc. (BIIB), COMPASS Pathways plc (CMPS), Collegium Pharmaceutical, Inc. (COLL), Bright Minds Biosciences Inc. (DRUG), Eledon Pharmaceuticals, Inc. (ELDN), GH Research PLC (GHRS), Jazz Pharmaceuticals plc (JAZZ), MediciNova, Inc. (MNOV), Neurocrine Biosciences, Inc. (NBIX), Neumora Therapeutics, Inc. Common Stock (NMRA), Ovid Therapeutics Inc. (OVID), Praxis Precision Medicines, Inc. (PRAX), Rapport Therapeutics, Inc. Common Stock (RAPP), Relmada Therapeutics, Inc. (RLMD), Stoke Therapeutics, Inc. (STOK), Supernus Pharmaceuticals, Inc. (SUPN), Tonix Pharmaceuticals Holding Corp. (TNXP), Xenon Pharmaceuticals Inc. (XENE). 1 name below the floor was excluded from the statistics: CGTX.

Window and company universe

This update covers Neurology and CNS Therapeutics over the 14-day window September 14–28, 2026; market data runs through September 28, 2026. The universe is the 25 listed companies whose core business is Neurology and CNS Therapeutics under NeuraCap's industry classification, subject to a $100M market-capitalisation floor so that very small, loosely related names cannot dominate the movers and statistics. Companies covered: ACADIA Pharmaceuticals Inc. (ACAD), Alpha Cognition Inc (ACOG), Amylyx Pharmaceuticals, Inc. (AMLX), Alto Neuroscience, Inc. (ANRO), Anavex Life Sciences Corp. (AVXL), Axsome Therapeutics, Inc. (AXSM), Biohaven Ltd. (BHVN), Biogen Inc. (BIIB), COMPASS Pathways plc (CMPS), Collegium Pharmaceutical, Inc. (COLL), Bright Minds Biosciences Inc. (DRUG), Eledon Pharmaceuticals, Inc. (ELDN), GH Research PLC (GHRS), Jazz Pharmaceuticals plc (JAZZ), MediciNova, Inc. (MNOV), Neurocrine Biosciences, Inc. (NBIX), Neumora Therapeutics, Inc. Common Stock (NMRA), Ovid Therapeutics Inc. (OVID), Praxis Precision Medicines, Inc. (PRAX), Rapport Therapeutics, Inc. Common Stock (RAPP), Relmada Therapeutics, Inc. (RLMD), Stoke Therapeutics, Inc. (STOK), Supernus Pharmaceuticals, Inc. (SUPN), Tonix Pharmaceuticals Holding Corp. (TNXP), Xenon Pharmaceuticals Inc. (XENE). 1 name below the floor was excluded from the statistics: CGTX.

How the moves and statistics are computed

Each company's period move is the change in closing price from the last close before the window to the last close inside it (close-to-close). The sector median is the median of those moves across the covered names; the index return is computed the same way for the S&P 500 over the same dates. The largest single-day move inside the window is shown for each mover. Movers are the largest gainers and losers by period move; the attribution cards prefer movers whose in-window record explains the move. Movers carry the valuation tier assigned in the standing sector study (the latest NeuraCap sector outlook) where that study rated them.

Events, news and how a move is attributed

Company events are the 8-K filings made inside the window; news items are publisher-sourced headlines for the window, admitted in a fixed order of reliability: SEC filings first, then company press releases and investor-relations communications, then established outlets (Reuters, CNBC, The Wall Street Journal, Barron's and peers). Video and social platforms are never used. A move is linked to an event only when the event falls inside the window and only in calibrated language; where nothing in the record explains a move, the update says so rather than speculating. Every event links to its source.

Transactions in the window and the trailing record

Transactions are taken from SEC filings by announcement date; 0 were announced inside the window. The trailing record of 32 recorded transactions provides the reference multiples (EV over last-twelve-month revenue or EBITDA at announcement, as disclosed). A value whose own citation describes something other than the price paid is not shown as the deal value; transactions where the acquirer and the target are the same entity are treated as reorganisations and excluded.

Sources

Prices and index levels are market data through September 28, 2026; filings are the companies' SEC filings on EDGAR; press releases are the companies' own; other news items are from the established outlets named on each card; Treasury yields are published by the U.S. Department of the Treasury. Every figure and every event in the update links to its record.

Interpretation and important notice

'Why it matters', 'why the deal happened' and the what-it-means page are NeuraCap analytical views drawn from the recorded evidence, labelled as such. The update is informational: it is not investment advice, not a recommendation to buy or sell any security and not an offer of any kind.

This report is published for information only. It is not a recommendation to buy or sell any security, an offer or solicitation, an appraisal or a fairness opinion, and no fiduciary relationship is created by reading it. Multiples that fail NeuraCap’s plausibility gates are excluded and never plotted. See the full methodology and the disclaimer.

Want this analysis for a company in Neurology and CNS Therapeutics?

Company valuation reports run the same method against a single business — public or private.